Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Navigate: Correlations HPO
There is one clinical trial.
An Open-label study for patients who completed the previous studies, PTI-125-02 or PTI-125-03. Additional new patients will be included for a total of 100 patients enrolled for this study.
Description: Safety and tolerability of Sumifilam (PTI-125)
Measure: Safety and Tolerability Time: Day 1 to Month 12Description: Biomarkers of AD pathology, neurodegeneration and neuroinflammation
Measure: Cerebrospinal fluid P-tau, neurofilament light chain, neurogranin, Total Tau, YKL-40, Abeta42 (pg/mL) Time: Screening to Month 12Description: Assess cognitive symptoms of dementia
Measure: Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog-11) Time: Day 1 to Month 12Description: Assess behavioral symptoms
Measure: Neuropsychiatric Index (NPI) Time: Day 1 to Month 12Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports